Innovhem proudly shares its latest scientific publication in Haematologica Journal, highlighting our commitment to advancing hematology research. In this study, Innovhem’s team used its expertise and technical platforms to explore how treatments work, assess their...
Aventure France 2030 ! 🏆 Hier, à Paris, se tenait le Comité interministériel de l’innovation C2i. Nous sommes fiers de faire partie de l’Aventure France 2030 ! pour rapprocher le futur et contribuer à l’excellence française dans la recherche...
Another step forward in the fight against sickle cell disease ! On the occasion of the state visit to France by Their Majesties King Frederik X and Queen Mary of Denmark, the 1st of April, Novo Nordisk signed a letter of intent to support the REVE (REVolutionizing...
Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting. One poster presentation to feature new data, highlighting the single-cell quantification of HbF and HbS on patients treated with hydroxyurea. Innovhem is a French...
Innovhem’s patents protect our BIOMARKERS : An important news ! SINGLE CELL QUANTIFICATION OF FETAL HEMOGLOBIN patent has been issued in France, Nigeria and in the US. And our 2 patents cover INTRAVASCULAR HEMOLYSIS ASSAY in Europe and in the US. Stay tuned for...
HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will improve intra vascular hemolysis and will increase the total mass of hemoglobin with beneficial effects on organ...
